Geoffrey Oxnard, MD
Associate Professor
Boston University Chobanian & Avedisian School of Medicine
Dept of Medicine
Hematology & Medical Oncology

MD, University of Chicago



Geoffrey Oxnard is a thoracic oncologist at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School. The aims of Dr. Oxnard’s research are to develop clinical applications for cancer genotyping technologies to advance precision cancer care.

Dr. Oxnard has published extensively on sensitivity and resistance to EGFR kinase inhibitors in lung cancer with a focus on the clinical biology of the EGFR T790M mutation. More recently his research has focused on genomic analysis of plasma cell-free DNA as a diagnostic to assist in treatment planning, response monitoring, and cancer detection.

Dr. Oxnard received his BA in chemistry from Harvard University and his MD from the University of Chicago-Pritzker School of Medicine. He served his residency in internal medicine at Massachusetts General Hospital and completed his fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center, joining the Dana-Farber faculty in 2011.

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, Antonarakis ES, Li G, Huang RSP, Casanova-Salas I, Vivancos A, Carles J, Ross JS, Schrock AB, Oxnard GR, Mateo J. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. JCO Precis Oncol. 2022 07; 6:e2200195. PMID: 35820087; PMCID: PMC9307307; DOI: 10.1200/PO.22.00195;
     
  2. Mata DA, Harries L, Williams EA, Hiemenz MC, Decker B, Tse JY, Janovitz T, Ferguson DC, Speece IA, Margolis ML, Mathews B, Fedorchak K, Killian JK, Xiao J, Tolba KA, Ramkissoon S, Vergilio JA, Elvin JA, Oxnard GR, Ross JS, Huang RSP. Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer. Arch Pathol Lab Med. 2022 Jun 30. PMID: 35771716
     
  3. Kim DW, Gadgeel S, Gettinger SN, Riely GJ, Oxnard GR, Mekhail T, Schmid P, Dowlati A, Heist RS, Wozniak AJ, Singh J, Cha E, Spahn J, Ou SI. Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC. JTO Clin Res Rep. 2022 Aug; 3(8):100367. PMID: 35875467; PMCID: PMC9304608; DOI: 10.1016/j.jtocrr.2022.100367;
     
  4. Kehl KL, Zahrieh D, Yang P, Hillman SL, Tan AD, Sands JM, Oxnard GR, Gillaspie EA, Wigle D, Malik S, Stinchcombe TE, Ramalingam SS, Kelly K, Govindan R, Mandrekar SJ, Osarogiagbon RU, Kozono D. Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). JAMA Oncol. 2022 05 01; 8(5):717-728. PMID: 35297944; PMCID: PMC8931674; DOI: 10.1001/jamaoncol.2022.0039;
     
  5. Dagogo-Jack I, Oxnard GR, Evangelist M, Digumarthy SR, Lin JJ, Gainor JF, Murphy JF, Rabin MS, Heist RS, Muzikansky A, Shaw AT. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse. JCO Precis Oncol. 2022 05; 6:e2100522. PMID: 35584349
     
  6. Antonarakis ES, Tierno M, Fisher V, Tukachinsky H, Alexander S, Hamdani O, Hiemenz MC, Huang RSP, Oxnard GR, Graf RP. Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer. Prostate. 2022 05; 82(7):867-875. PMID: 35286728; PMCID: PMC9314037; DOI: 10.1002/pros.24331;
     
  7. Dercle L, Zhao B, Gönen M, Moskowitz CS, Firas A, Beylergil V, Connors DE, Yang H, Lu L, Fojo T, Carvajal R, Karovic S, Maitland ML, Goldmacher GV, Oxnard GR, Postow MA, Schwartz LH. Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis. JAMA Oncol. 2022 Mar 01; 8(3):385-392. PMID: 35050320; PMCID: PMC8778619; DOI: 10.1001/jamaoncol.2021.6818;
     
  8. Mata DA, Williams EA, Sokol E, Oxnard GR, Fleischmann Z, Tse JY, Decker B. Prevalence of UV Mutational Signatures Among Cutaneous Primary Tumors. JAMA Netw Open. 2022 03 01; 5(3):e223833. PMID: 35319765; PMCID: PMC8943639; DOI: 10.1001/jamanetworkopen.2022.3833;
     
  9. Graf RP, Fisher V, Weberpals J, Gjoerup O, Tierno MB, Huang RSP, Sayegh N, Lin DI, Raskina K, Schrock AB, Severson E, Haberberger JF, Ross JS, Creeden J, Levy MA, Alexander BM, Oxnard GR, Agarwal N. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2022 03 01; 5(3):e225394. PMID: 35357449; PMCID: PMC8972027; DOI: 10.1001/jamanetworkopen.2022.5394;
     
  10. Williamson DFK, Marris SRN, Rojas-Rudilla V, Bruce JL, Paweletz CP, Oxnard GR, Sholl LM, Dong F. Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR. PLoS One. 2022; 17(2):e0264201. PMID: 35202431; PMCID: PMC8870499; DOI: 10.1371/journal.pone.0264201;
     
Showing 10 of 156 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 156 publications over 19 distinct years, with a maximum of 22 publications in 2020

YearPublications
20041
20052
20061
20072
20081
20091
20104
20118
20126
20139
20145
201517
201614
20178
201816
20199
202022
202118
202212
Contact for Mentoring:

820 Harrison Ave Boston MA
Google Map


Oxnard's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department